Developing point-of-care CAR T manufacturing
European Pharmaceutical Review
DECEMBER 27, 2023
Second, the production and delivery of CAR T cells necessitates close collaboration between the pharma industry and academic (usually transplant) departments. On the logistics side, the in-house process eliminates, in principle, the need for cryopreservation of the CAR T-cell products. US Food and Drug Administration.
Let's personalize your content